MA50636A - Compositions et procédés pour inhiber l'activité d'arginase - Google Patents

Compositions et procédés pour inhiber l'activité d'arginase

Info

Publication number
MA50636A
MA50636A MA050636A MA50636A MA50636A MA 50636 A MA50636 A MA 50636A MA 050636 A MA050636 A MA 050636A MA 50636 A MA50636 A MA 50636A MA 50636 A MA50636 A MA 50636A
Authority
MA
Morocco
Prior art keywords
arginase
inhibiting
compositions
activity
methods
Prior art date
Application number
MA050636A
Other languages
English (en)
Inventor
Jim Li
Eric B Sjogren
Zandt Michael Van
Darren Whitehouse
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of MA50636A publication Critical patent/MA50636A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
MA050636A 2015-10-30 2016-10-28 Compositions et procédés pour inhiber l'activité d'arginase MA50636A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US201662323034P 2016-04-15 2016-04-15

Publications (1)

Publication Number Publication Date
MA50636A true MA50636A (fr) 2021-04-14

Family

ID=58631120

Family Applications (2)

Application Number Title Priority Date Filing Date
MA050636A MA50636A (fr) 2015-10-30 2016-10-28 Compositions et procédés pour inhiber l'activité d'arginase
MA43131A MA43131B1 (fr) 2015-10-30 2016-10-28 Compositions et procédés d'inhibition de l'activité de l'arginase

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA43131A MA43131B1 (fr) 2015-10-30 2016-10-28 Compositions et procédés d'inhibition de l'activité de l'arginase

Country Status (36)

Country Link
US (4) US10065974B2 (fr)
EP (3) EP3693375B1 (fr)
JP (3) JP6833844B2 (fr)
KR (2) KR20220118559A (fr)
CN (4) CN108271371B (fr)
AU (3) AU2016343656B2 (fr)
BR (3) BR112018008746B1 (fr)
CA (1) CA3003271A1 (fr)
CL (4) CL2018001134A1 (fr)
CO (1) CO2018004750A2 (fr)
CR (3) CR20210390A (fr)
CY (1) CY1123557T1 (fr)
DK (2) DK3368541T3 (fr)
EA (1) EA038276B1 (fr)
EC (1) ECSP18040250A (fr)
ES (3) ES2910928T3 (fr)
HR (1) HRP20201046T1 (fr)
HU (1) HUE054972T2 (fr)
IL (3) IL258731B (fr)
LT (1) LT3368541T (fr)
MA (2) MA50636A (fr)
MD (1) MD3368541T2 (fr)
MX (1) MX2018005294A (fr)
MY (1) MY201783A (fr)
NZ (1) NZ742742A (fr)
PH (2) PH12022551082A1 (fr)
PL (1) PL3368541T3 (fr)
PT (1) PT3368541T (fr)
RS (1) RS60695B1 (fr)
SG (4) SG11201802961PA (fr)
SI (1) SI3368541T1 (fr)
SM (1) SMT202000469T1 (fr)
TW (3) TWI775556B (fr)
UA (1) UA125289C2 (fr)
WO (1) WO2017075363A1 (fr)
ZA (4) ZA201803556B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201503168VA (en) 2010-04-22 2015-06-29 Mars Inc Inhibitors of arginase and their therapeutic applications
HRP20160305T1 (hr) 2010-10-26 2016-07-01 Mars, Incorporated Borati kao inhibitori arginaze
SG11201802961PA (en) 2015-10-30 2018-05-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
JP2020502259A (ja) * 2016-11-08 2020-01-23 カリセラ バイオサイエンシズ，インコーポレイテッド アルギナーゼ阻害剤併用療法
CN114989205A (zh) * 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
KR20200008578A (ko) * 2017-05-12 2020-01-28 칼리테라 바이오사이언시즈, 인코포레이티드 (3R,4S)-3-아세트아미도-4-알릴-N-(tert-부틸)피롤리딘-3-카복스아미드의 제조방법
CN111491937A (zh) * 2017-12-22 2020-08-04 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的杂环化合物
CN117186134A (zh) 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
AU2019229978B2 (en) 2018-03-05 2024-05-30 Arcus Biosciences, Inc. Arginase inhibitors
EP3765006A4 (fr) * 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. Inhibiteurs d'arginase et procédés d'utilisation
WO2019186497A1 (fr) 2018-03-29 2019-10-03 Oncoarendi Therapeutics S.A. Dérivés de pipéridine dipeptidiques
WO2019245890A1 (fr) 2018-06-20 2019-12-26 Merck Sharp & Dohme Corp. Inhibiteurs d'arginase et procédés d'utilisation
TWI828800B (zh) 2018-11-16 2024-01-11 美商阿克思生物科學有限公司 Arg1及/或arg2之抑制劑
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
EP3897622B1 (fr) 2018-12-18 2026-01-14 Merck Sharp & Dohme LLC Inhibiteurs d'arginase et procédés d'utilisation
WO2020160707A1 (fr) * 2019-02-06 2020-08-13 Guangdong Newopp Biopharmaceuticals Co., Ltd. Acides alkylboroniques en tant qu'inhibiteurs d'arginase
CA3138544A1 (fr) * 2019-05-02 2020-11-05 Aclaris Therapeutics, Inc. Pyrrolopyridines substituees en tant qu'inhibiteurs de jak
WO2021014380A1 (fr) * 2019-07-23 2021-01-28 Astrazeneca Ab Inhibiteurs d'arginase et procédés d'utilisation associés
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
AU2020384481B2 (en) 2019-11-12 2025-12-11 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof
EP4087583B1 (fr) * 2020-01-07 2026-04-22 Merck Sharp & Dohme LLC Inhibiteurs d'arginase et méthodes d'utilisation
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
TW202216662A (zh) 2020-07-17 2022-05-01 美商英塞特公司 製備精胺酸酶抑制劑及其合成中間物之方法
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US20240190876A1 (en) 2022-10-21 2024-06-13 Incyte Corporation Tricyclic Urea Compounds As JAK2 V617F Inhibitors
JP2026509874A (ja) 2023-03-13 2026-03-25 インサイト・コーポレイション キナーゼ阻害剤としての二環式尿素
US20260098044A1 (en) 2024-10-04 2026-04-09 Incyte Corporation Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
CA2415174A1 (fr) 2000-07-06 2002-01-17 Thomas W. Bell Procedes et trousses de detection de composes d'arginine
CA2431080A1 (fr) 2003-06-02 2004-12-02 Catherine Adele O'brien Amelioration de l'immunite contre le cancer par l'intermediaire de l'inhibition de l'arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (fr) 2003-08-07 2014-01-29 Allergan, Inc. Compositions d'administration d'agents therapeutiques dans les yeux
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2007005620A2 (fr) 2005-07-01 2007-01-11 The Johns Hopkins University Arginase ii: traitement cible du vieillissement cardiaque et de l'insuffisance cardiaque
CN101755130B (zh) 2007-07-12 2012-10-17 山洋电气株式会社 双重反转式轴流鼓风机
JP5421272B2 (ja) * 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
US20110129456A1 (en) * 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
LT2389352T (lt) 2009-01-26 2019-06-10 The Trustees Of The University Of Pennsylvania Arginazės inhibitoriai ir naudojimo būdai
SG10201503168VA (en) 2010-04-22 2015-06-29 Mars Inc Inhibitors of arginase and their therapeutic applications
HRP20160305T1 (hr) * 2010-10-26 2016-07-01 Mars, Incorporated Borati kao inhibitori arginaze
CA2824599C (fr) 2010-12-31 2020-03-10 Astrazeneca Uk Limited Inhibiteurs de l'arginase et leurs procedes d'utilisation
WO2013059437A1 (fr) 2011-10-19 2013-04-25 Mars, Incorporated Inhibiteurs de l'arginase et leurs applications thérapeutiques
JP6073343B2 (ja) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
CN104540836B (zh) * 2012-04-18 2016-11-09 马尔斯公司 作为精氨酸酶抑制剂的环约束类似物
TW201427664A (zh) * 2012-11-02 2014-07-16 Pharmacyclics Inc Ｔｅｃ家族激酶抑制劑佐劑療法
EA201690746A1 (ru) * 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
CN105879030A (zh) * 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
CN107405404A (zh) * 2015-03-20 2017-11-28 塞米·欧尤·奥皮约 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途
US10143699B2 (en) 2015-06-23 2018-12-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
SG11201802961PA (en) 2015-10-30 2018-05-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Also Published As

Publication number Publication date
SI3368541T1 (sl) 2020-10-30
KR102434308B1 (ko) 2022-08-19
AU2020286278B2 (en) 2022-03-17
TW202146028A (zh) 2021-12-16
CO2018004750A2 (es) 2018-10-31
BR112018008746A8 (pt) 2019-02-26
CN108271371A (zh) 2018-07-10
ECSP18040250A (es) 2018-10-31
BR112018008746A2 (pt) 2018-10-30
AU2016343656B2 (en) 2020-09-17
JP2021075543A (ja) 2021-05-20
IL258731B (en) 2021-04-29
EP3693375B1 (fr) 2022-02-16
HK1252560A1 (en) 2019-05-31
CN113201002A (zh) 2021-08-03
ES2991555T3 (es) 2024-12-04
JP6833844B2 (ja) 2021-02-24
IL281503A (en) 2021-04-29
IL258731A (en) 2018-06-28
ZA201907091B (en) 2021-05-26
US10065974B2 (en) 2018-09-04
AU2022203703A1 (en) 2022-06-16
KR20220118559A (ko) 2022-08-25
SG10201911402YA (en) 2020-02-27
US20170121352A1 (en) 2017-05-04
WO2017075363A1 (fr) 2017-05-04
US20180346489A1 (en) 2018-12-06
SG10201911406TA (en) 2020-01-30
PT3368541T (pt) 2020-07-06
IL281503B (en) 2022-01-01
UA125289C2 (uk) 2022-02-16
PH12022551082A1 (en) 2023-03-13
US20200223872A1 (en) 2020-07-16
KR20180084063A (ko) 2018-07-24
CL2018001134A1 (es) 2018-10-26
EP3693375A1 (fr) 2020-08-12
MY201783A (en) 2024-03-18
DK3368541T3 (da) 2020-06-29
IL288225A (en) 2022-01-01
HUE054972T2 (hu) 2021-10-28
NZ742742A (en) 2023-04-28
SG10202003966RA (en) 2020-06-29
CL2019000821A1 (es) 2019-08-09
PH12018500899A1 (en) 2018-10-29
EP3368541B1 (fr) 2020-05-27
SG11201802961PA (en) 2018-05-30
TW202110858A (zh) 2021-03-16
CN113150015A (zh) 2021-07-23
EP3368541A1 (fr) 2018-09-05
JP2018533582A (ja) 2018-11-15
CR20210389A (es) 2021-09-16
ZA201803556B (en) 2021-02-24
CL2019000819A1 (es) 2019-08-09
JP2022071010A (ja) 2022-05-13
MX2018005294A (es) 2018-09-21
TW201726692A (zh) 2017-08-01
AU2016343656A1 (en) 2018-06-07
US10851118B2 (en) 2020-12-01
ZA201907093B (en) 2021-03-31
PH12018500899B1 (en) 2023-02-08
US20210061822A1 (en) 2021-03-04
EP4011887A1 (fr) 2022-06-15
ES2910928T3 (es) 2022-05-17
RS60695B1 (sr) 2020-09-30
BR122020022280B1 (pt) 2022-05-03
PL3368541T3 (pl) 2020-11-02
SMT202000469T1 (it) 2020-11-10
CN113150016A (zh) 2021-07-23
US10844080B2 (en) 2020-11-24
CR20180282A (es) 2018-11-30
BR112018008746B1 (pt) 2021-11-16
CN108271371B (zh) 2021-02-09
CA3003271A1 (fr) 2017-05-04
ES2808988T3 (es) 2021-03-02
BR122020022275B1 (pt) 2022-05-03
EA038276B1 (ru) 2021-08-04
EP3368541A4 (fr) 2019-07-17
CL2019000820A1 (es) 2019-08-09
HRP20201046T1 (hr) 2020-10-16
TWI710565B (zh) 2020-11-21
JP7032583B2 (ja) 2022-03-08
EA201891057A1 (ru) 2018-12-28
AU2020286278A1 (en) 2021-01-14
CR20210390A (es) 2021-10-19
TWI734630B (zh) 2021-07-21
DK4011887T3 (da) 2024-10-28
TWI775556B (zh) 2022-08-21
EP4011887B1 (fr) 2024-07-31
MA43131B1 (fr) 2020-07-29
MD3368541T2 (ro) 2020-09-30
CY1123557T1 (el) 2022-03-24
LT3368541T (lt) 2020-09-25
ZA201907092B (en) 2021-04-28

Similar Documents

Publication Publication Date Title
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
MA42269A (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
IL267532B (en) Preparations and methods for inhibiting arginase activity
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
EP3353309A4 (fr) Compositions et méthodes pour l'édition génomique
MA45270A (fr) Compositions d'oligonucléotides et procédés associés
EP3325017A4 (fr) Compositions d'oligonucléotides et procédés associés
EP3386484A4 (fr) Compositions et procédés permettant d'administrer des agents thérapeutiques
EP3635100A4 (fr) Compositions et procédés pour exprimer l'otoferline
EP3273944A4 (fr) Compositions et procédés permettant d'administrer des agents de type biomacromolécule
EP3386550A4 (fr) Procédés et compositions pour la fabrication et l'utilisation d'acides nucléiques de guidage
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA41253A (fr) Composés, compositions et procédés pour augmenter l'activité du cftr
EP3359693A4 (fr) Procédés et compositions pour enrichissement de produits d'amplification
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
EP3267995A4 (fr) Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement de la fibrose
EP3289064A4 (fr) Compositions et procédés pour la détection d'allergènes
EP3349743A4 (fr) Procédés et compositions d'inhibition de l'interaction dcn1-ubc12
EP3302558A4 (fr) Agents anticancéreux et procédés d'utilisation
EP3488018A4 (fr) Procédés et compositions pour l'identification de protéines
EP3389673A4 (fr) Procédés et compositions pour l'administration de polynucléotides
EP3373950A4 (fr) Procédés et compositions d'évaluation de spécificités d'anticorps
EP3458448A4 (fr) Procédés d'utilisation d'inhibiteurs de fasn
EP3261631C0 (fr) Inhibition de l'activité d'olig2
MA40512A (fr) Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants